New Market Research Supports NeutraSal® Efficacy in the Relieving Xerostomia (Dry Mouth) in Sjögren’s Syndrome Subjects

Share Article

Invado Pharmaceuticals today announced the completion of a market research study utilizing NeutraSal® (supersaturated calcium phosphate rinse) as a treatment for xerostomia, or dry mouth, in subjects with Sjogren’s Syndrome. 90% of the subjects were satisfied with the medication with no adverse effects reported.

The findings of this market research are very promising and further demonstrate the efficacy of NeutraSal with the absence of any adverse effects.

Invado Pharmaceuticals today announced the completion of a market research study utilizing NeutraSal® (supersaturated calcium phosphate rinse) as a treatment for xerostomia, or dry mouth, in subjects with Sjogren’s Syndrome. Forty subjects (39 female, 1 male) with a median age of 59.4 years with a previous diagnosis of primary or secondary Sjögren’s syndrome and subsequent xerostomia agreed to evaluate the efficacy of NeutraSal® for 28 days. Subjects at baseline were given a dry mouth questionnaire and asked to complete a self-assessment 28 days later. Results were compared against the baseline questions.
Patients on average reported dryness of mouth of 3.7 and dryness of the tongue of 4.0 based on a scale of 1 to 10. (1= Dry as Desert and 10=Normal)

Results: The use of NeutraSal® showed a dramatic improvement in symptomatic relief of xerostomia based on the dry mouth questionnaire.
The percent reporting improvement were as follows:

  • Improvement in Ability to Speak -44%
  • Less dry mouth when eating -76%
  • Improvement in swallowing dry food-28%
  • Noted increase in saliva-49%
  • Noted improvement in sleep-61%

The average score for dryness of the mouth improved from (3.6) to (8.2) and for the tongue from (4.0) to (8.1) based on the 1-10 scale.
No adverse effects with NeutraSal® treatment were reported.
The duration of action for NeutraSal® lasted an average of 71 minutes.
The average dose was 2.3 times per day including a bedtime dose.    
90% of subjects were satisfied with NeutraSal®.

About NeutraSal®
NeutraSal® (supersaturated calcium phosphate rinse) is an oral rinse that may be used for relief of dryness of the oral mucosa when hyposalivation results from the following: surgery, radiotherapy near the salivary glands, chemotherapy, infection or dysfunction of the salivary glands; fever; emotional factors such as fear or anxiety; obstruction of the salivary ducts; and Sjögren’s syndrome NeutraSal® may be used as part of an oral hygiene program for patients with dry mouth. NeutraSal® also provides intensive hygiene of the oral cavity.

For information, please go to http://www.neutrasal.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Edward Kobus
Invado Pharmaceuticals
(866) 963-8881
Email >
Visit website